Novo Nordisk Signs ActiveSight for Protein Crystallography

Jan 23, 2006

NEW YORK, Jan. 23 (GenomeWeb News) - ActiveSight has signed a deal with Novo Nordisk to provide protein crystallography, the company announced today.

Terms of the agreement were not disclosed.

ActiveSight is a division of Rigaku that features a portfolio of drug targets for co-crystallography.

Breaking News

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.